Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.
Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.
1457 of 1457 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Sunshine Lake PharmaPrivate | 5 assets: 2 Ph 3, 3 Ph 1 | Clifutinib BesylatePhase 3 · Acute Myeloid Leukemia | 11 Apr 2027HECN30227 · Phase 1 | — | — | — | — |
Suven Life SciencesSUVEN · NSE | 2 assets: 1 Ph 3, 1 Ph 2 | MasupirdinePhase 3 · Alzheimer's DiseasePartial signal | Dec 2026Masupirdine · Phase 3 | — | — | — | $33M |
Suzhou Ribo Life Science6938 · HKEX | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | QLC7401Phase 3 · Atherosclerotic Cardiovascular Disease | 7 Oct 2027QLC7401 · Phase 3 | — | — | — | $39M |
Suzhou Zelgen Biopharmaceuticals688266 · SSE STAR Market | 2 assets: 2 Ph 3 | jaktinibPhase 3 · Atopic DermatitisPartial signal | Feb 2027jaktinib · Phase 1 | — | $18MDec 2025 | — | $60M |
Swedish Orphan Biovitrum AB (publ)SOBI · Nasdaq Stockholm | 6 assets: 3 approved, 1 Ph 3, 1 Ph 2, 1 other | InotersenUS approval withdrawn · Transthyretin Amyloidosis with PolyneuropathyReliable signal | Mar 2027Olezarsen · Phase 3 | — | — | — | — |
TaiMed Biologics4147 · TPEx | 2 assets: 1 approved, 1 Ph 2 | TMB-365 / TMB-380Phase 2 · HIV | May 2027TMB-365 / TMB-380 · Phase 2 | — | — | — | — |
Tasly Pharmaceutical Group600535 · SSE | 6 assets: 2 Ph 3, 4 Ph 2 | QiShenYiQiPhase 3 · Heart FailurePartial signal | 31 Dec 2026Jia Shen Tablet · Phase 2 | — | — | — | $118M |
Teijin3401 · TSE | 5 assets: 3 approved, 1 Ph 3, 1 Ph 2 | TrelagliptinPhase 3 · Type 2 DiabetesPartial signal | Aug 2027palopegteriparatide · Phase 3 | — | — | — | — |
TG THERAPEUTICS, INC.TGTX · Nasdaq | 2 assets: 1 approved, 1 Ph 1 | Azercabtagene zapreleucelPhase 1 · Multiple Sclerosis | 1 Dec 2026Azercabtagene zapreleucel · Phase 1 | — | $505MSep 2026 | Cash-flow positive | $236M |
Tiziana Life Sciences Ltd.TLSA · Nasdaq | 1 asset: 1 Ph 2 | ForalumabPhase 2 · Multiple Sclerosis | 1 Apr 2027Foralumab · Phase 2 | — | $3.7MDec 2024 | ~9.7 qtrs | $5.2M |
Tonghua Dongbao Pharmaceutical600867 · SSE | 2 assets: 1 Ph 3, 1 Ph 2 | THDB0206Phase 3 · Type 2 DiabetesPartial signal | None on record | — | $205MDec 2025 | — | — |
TransgeneTNG · Euronext Paris | 1 asset: 1 Ph 2 | T101Phase 2 · Chronic Hepatitis B | None on record | — | — | — | — |
TransThera Sciences (Nanjing), Inc.2617 · HKEX | 1 asset: 1 Ph 3 | TinengotinibPhase 3 · CholangiocarcinomaWeak signal | Dec 2026Tinengotinib · Phase 3 | — | — | — | — |
TScan Therapeutics, Inc.TCRX · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | TSC-101Phase 3 · Hematologic Malignancies | Jun 2029TSC-101 · Phase 3 | — | $78MSep 2026 | ~2.8 qtrs | $91M |
TYK Medicines, Inc.2410 · HKEX | 1 asset: 1 Ph 3 | AsandeutertinibPhase 3 · Non-Small Cell Lung CancerWeak signal | 1 Dec 2027Asandeutertinib · Phase 2 | — | — | — | $34M |
UCBUCBJY · OTC | 16 assets: 10 approved, 1 Ph 3, 3 Ph 2, 2 Ph 1 | Staccato AlprazolamPhase 3 · EpilepsyReliable signal | 21 Dec 2026bimekizumab · Phase 3 | —no price since 18 Aug 2026 | — | — | ~$1.9B |
Upsher-Smith Laboratories, LLC6472 · TWSE | 2 assets: 2 approved | Approved assets only | None on record | — | — | — | — |
Vaccinex, Inc.VCNX · OTC | 1 asset: 1 Ph 2 | PepinemabPhase 1/2 · Alzheimer's DiseaseWeak signal | 31 Dec 2028Pepinemab · Phase 1/2 | —no price since 18 Aug 2026 | $1.1MDec 2024 | Ended Jan 2025 | $13M |
VaxxinityVAXX · OTC | 2 assets: 1 Ph 2, 1 Ph 1 | UB-311Phase 2 · Early Alzheimer's Disease | None on record | —no price since 17 Aug 2026 | $31MDec 2023 | Ended Jul 2024 | $36M |
Vigonvita Life Sciences2630 · HKEX | 2 assets: 2 Ph 2 | LV232Phase 2 · Major Depressive DisorderWeak signal | 1 Sep 2027LV232 · Phase 2 | — | — | — | — |
VISEN Pharmaceuticals2561 · HKEX | 2 assets: 2 approved | Approved assets only | Aug 2027palopegteriparatide · Phase 3 | — | — | — | — |
Voronoi, Inc310210 · KOSDAQ | 2 assets: 2 Ph 2 | EnozertinibPhase 1/2 · Non-Small Cell Lung Cancer | Dec 2026Enozertinib · Phase 1 | — | — | — | — |
Windtree TherapeuticsWINT · OTC | 1 asset: 1 Ph 2 | rostafuroxinPhase 2 · Resistant Hypertension with Adducin/Ouabain Polymorphisms | None on record | —no price since 14 Aug 2026 | $0.2MSep 2025 | Ended Oct 2025 | $8.6M |
Wuhan YZY Biopharma Co., Ltd.2496 · HKEX | 2 assets: 1 Ph 2, 1 Ph 1 | M701Phase 1/2 · Non-Small Cell Lung Cancer | None on record | — | $14MDec 2025 | ~4.8 qtrs | — |
XBiotechXBIT · Nasdaq | 2 assets: 2 Ph 2 | NatrunixPhase 2 · Rheumatoid ArthritisPartial signal | 15 Jan 2027Natrunix · Phase 2 | — | $105MSep 2026 | ~10.3 qtrs | $47M |
Xbrane Biopharma ABXBRANE · Nasdaq Stockholm | 1 asset: 1 Ph 3 | Ranibizumab (Ximluci)Phase 3 · Age-Related Macular Degeneration | None on record | — | — | — | — |
Xiamen Amoytop Biotech Co., Ltd.688278 · SSE | 1 asset: 1 Ph 1 | ACT201Phase 1 · Chronic Hepatitis B | Feb 2027ACT201 · Phase 1 | — | — | — | — |
Xuanzhu Biopharmaceutical2575 · HKEX | 4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1 | BireociclibPhase 3 · HR+/HER2- Metastatic Breast CancerReliable signal | None on record | — | — | — | $26M |
Yiling Pharmaceutical Inc.Private | 1 asset: 1 Ph 1 | FinaminePhase 1 · Parkinson's DiseaseWeak signal | None on record | — | — | — | — |
Yuhan Corporation000100 · KOSPI | 7 assets: 1 approved, 1 Ph 3, 2 Ph 2, 3 other | SarpogrelatePhase 3 · Atherosclerotic Cardiovascular Disease | 31 Dec 2026Lazertinib · Phase 1 | — | $241MDec 2025 | — | — |
Zai LabZLAB · Nasdaq | 7 assets: 6 approved, 1 Ph 1 | ZL-1503Phase 1 · Atopic Dermatitis | 24 Nov 2026Xanomeline/trospium chloride · Phase 3 | — | $560MSep 2026 | ~10.7 qtrs | $239M |
Zealand PharmaZEAL · Nasdaq Copenhagen | 6 assets: 2 approved, 2 Ph 3, 1 Ph 2, 1 Ph 1 | survodutidePhase 3 · ObesityReliable signal | 8 Dec 2026survodutide · Phase 1 | — | $2.2BMar 2026 | — | ~$224M |
Zeria Pharmaceutical Co., Ltd.4559 · TSE | 1 asset: 1 Ph 3 | PatiromerPhase 3 · Chronic Kidney DiseasePartial signal | 1 Dec 2029Patiromer · Phase 2 | — | — | — | — |
Zhejiang Hisun Pharmaceutical600267 · SSE | 1 asset: 1 Ph 3 | HyzetimibePhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record | — | — | — | $67M |
Zhejiang Huahai Pharmaceutical600521 · SSE | 1 asset: 1 Ph 2 | Hypidone (YL-0919)Phase 2 · Major Depressive DisorderPartial signal | None on record | — | — | — | $167M |
Zhejiang Jingxin Pharmaceutical Co., Ltd.002020 · SZSE | 2 assets: 1 Ph 2, 1 Ph 1 | JX11502MAPhase 2 · SchizophreniaPartial signal | None on record | — | — | — | — |
Zydus LifesciencesZYDUSLIFE · NSE | 5 assets: 1 approved, 3 Ph 3, 1 Ph 2 | DesidustatPhase 3 · Chronic Kidney DiseasePartial signal | 31 Dec 2026Saroglitazar · Phase 1 | — | — | — | $256M |
1ST Biotherapeutics, Inc.Private | 2 assets: 2 Ph 1 | FB-101Phase 1 · Parkinson's DiseaseWeak signal | Dec 2027FB-101 · Phase 1 | — | — | — | — |
35PharmaPrivate | 1 asset: 1 Ph 2 | HS235Phase 1/2 · Heart FailureWeak signal | Mar 2028HS235 · Phase 1/2 | — | — | — | — |
7 Hills Pharma, LLCPrivate | 1 asset: 1 Ph 2 | AlintegimodPhase 1/2 · Non-Small Cell Lung Cancer | 31 Dec 2027Alintegimod · Phase 1/2 | — | — | — | — |
89bioPrivate | 1 asset: 1 Ph 3 | PegozaferminPhase 3 · MASH / NASHPartial signal | 2 Mar 2027Pegozafermin · Phase 1 | — | $129MJun 2025 | Ended Oct 2025 | $421M |
A. MenariniPrivate | 8 assets: 3 approved, 5 Ph 3 | MirogabalinPhase 3 · Diabetic Peripheral Neuropathic PainReliable signal | Nov 2026Obicetrapib · Phase 3 | — | — | — | — |
A&G Pharmaceutical Inc.Private | 1 asset: 1 Ph 1 | AG-01Phase 1 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
A2 Biotherapeutics Inc.Private | 4 assets: 4 Ph 2 | A2B395Phase 1/2 · Non-Small Cell Lung Cancer | Dec 2026A2B530 · Phase 1/2 | — | — | — | — |
Aardvark TherapeuticsPrivate | 1 asset: 1 Ph 3 | ARD-101Phase 3 · Prader-Willi SyndromePartial signal | None on record | — | — | — | — |
AbcentraPrivate | 1 asset: 1 Ph 2 | OrticumabPhase 2 · Atherosclerotic Cardiovascular DiseasePartial signal | 8 Feb 2027Orticumab · Phase 2 | — | — | — | — |
AbelZeta Pharma, Inc.Private | 1 asset: 1 Ph 2 | Trovocabtagene autoleucel (C-CAR088)Phase 1/2 · Multiple MyelomaWeak signal | None on record | — | — | — | — |
ABL BioPrivate | 1 asset: 1 Ph 2 | givastomigPhase 2 · Gastric Cancer | Dec 2026givastomig · Phase 1 | — | — | — | — |
ABLi Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | Risvodetinib (IkT-148009)Phase 2 · Parkinson's DiseaseWeak signal | None on record | — | — | — | — |
Accord BioPharma Inc.Private | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Accord HealthcarePrivate | 2 assets: 1 approved, 1 Ph 3 | SerplulimabPhase 3 · Non-Small Cell Lung CancerReliable signal | 30 Dec 2026Serplulimab · Phase 1 | — | — | — | — |
Accro Bioscience LimitedPrivate | 1 asset: 1 Ph 2 | AC-201Phase 2 · Psoriasis | None on record | — | — | — | — |
| 1 asset: 1 Ph 2 | AC-101Phase 2 · Ulcerative Colitis | None on record | — | — | — | — | |
ACEA TherapeuticsPrivate | 1 asset: 1 Ph 2 | STI-6129Phase 1/2 · Multiple Myeloma | 31 Dec 2026STI-6129 · Phase 1/2 | — | — | — | — |
| 1 asset: 1 other | Dihydroergotamine mesylate/Dipyrone/Caffeine (Cefaliv)Migraine | None on record | — | — | — | — | |
Aclipse TherapeuticsPrivate | 1 asset: 1 Ph 3 | LobeglitazonePhase 3 · Type 2 DiabetesPartial signal | None on record | — | — | — | — |
Acrotech BiopharmaPrivate | 3 assets: 3 approved | Approved assets only | Dec 2026difamilast · Phase 3 | — | — | — | — |
Actio Biosciences, Inc.Private | 1 asset: 1 Ph 2 | ABS-1230Phase 2 · Epilepsy | Dec 2026ABS-1230 · Phase 1 | — | — | — | — |
Adamas PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
ADARx PharmaceuticalsPrivate | 1 asset: 1 Ph 1 | ADX-850Phase 1 · Hypertension | None on record | — | — | — | — |
AddimmunePrivate | 1 asset: 1 Ph 1 | AGT103-TPhase 1 · HIVWeak signal | None on record | — | — | — | — |
AddpharmaPrivate | 3 assets: 1 Ph 3, 1 Ph 1, 1 other | AD-209Phase 3 · HypertensionPartial signal | None on record | — | — | — | — |
Adiso TherapeuticsPrivate | 1 asset: 1 Ph 1 | PegmispotidePhase 1 · Ulcerative ColitisWeak signal | None on record | — | — | — | — |
Advanced BioDesignPrivate | 1 asset: 1 Ph 2 | ABD-3001Phase 1/2 · Acute Myeloid Leukemia | None on record | — | — | — | — |
ADvantage TherapeuticsPrivate | 1 asset: 1 Ph 2 | AD04Phase 2 · Alzheimer's Disease | Dec 2026AD04 · Phase 2 | — | — | — | — |
Advanz PharmaPrivate | 4 assets: 3 approved, 1 other | Aflibercept (Mynzepli)Age-Related Macular Degeneration | None on record | — | — | — | — |
Advenchen LaboratoriesPrivate | 2 assets: 2 Ph 3 | ApatinibPhase 3 · Non-Small Cell Lung CancerReliable signal | Jul 2027Apatinib · Phase 2 | — | — | — | — |
Advesya SASPrivate | 1 asset: 1 Ph 2 | CCTx-001Phase 1/2 · Acute Myeloid Leukemia | Jul 2027CCTx-001 · Phase 1/2 | — | — | — | — |
Aeira Pte. Ltd.Private | 1 asset: 1 Ph 3 | stapokibartPhase 3 · Atopic DermatitisReliable signal | Feb 2027stapokibart · Phase 3 | — | — | — | — |
Aelix TherapeuticsPrivate | 1 asset: 1 Ph 2 | HTI vaccine (ChAdOx1.HTI/MVA.HTI)Phase 2 · HIVPartial signal | None on record | — | — | — | — |
| 1 asset: 1 Ph 2 | AV078Phase 2 · Epilepsy | 1 Sep 2027AV078 · Phase 2 | — | — | — | — | |
AffaMed TherapeuticsPrivate | 2 assets: 1 approved, 1 Ph 3 | fasedienolPhase 3 · Social Anxiety DisorderPartial signal | None on record | — | — | — | — |
Affini-T Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | AFNT-211Phase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
AgeneBioPrivate | 1 asset: 1 Ph 3 | AGB101Phase 2/3 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
Agepha PharmaPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Agyany Pharma LtdPrivate | 1 asset: 1 Ph 3 | AmbroxolPhase 3 · Parkinson's DiseasePartial signal | None on record | — | — | — | — |
AiBtl BioPharmaPrivate | 1 asset: 1 Ph 2 | PDC-1421Phase 2 · Major Depressive DisorderPartial signal | 28 Feb 2028PDC-1421 · Phase 1/2 | — | — | — | — |
AirNexis TherapeuticsPrivate | 1 asset: 1 Ph 3 | HSK39004Phase 3 · Chronic Obstructive Pulmonary Disease | 11 Jun 2027HSK39004 · Phase 3 | — | — | — | — |
AJU PharmPrivate | 2 assets: 2 Ph 3 | Valsartan/amlodipine/chlorthalidone (AJU-C52)Phase 3 · HypertensionReliable signal | None on record | — | — | — | — |
Akros PharmaPrivate | 1 asset: 1 Ph 2 | JTT-861Phase 2 · Heart FailurePartial signal | None on record | — | — | — | — |
Alentis Therapeutics AGPrivate | 2 assets: 2 Ph 2 | ALE.P02Phase 1/2 · Non-Small Cell Lung Cancer | 15 Feb 2028ALE.P02 · Phase 1/2 | — | — | — | — |
| 3 assets: 2 approved, 1 Ph 2 | ALXN1820Phase 2 · ANCA-Associated Vasculitis | 7 Dec 2026Eculizumab · Phase 3 | — | — | — | — | |
AlfasigmaPrivate | 2 assets: 1 approved, 1 Ph 3 | filgotinibPhase 3 · Rheumatoid ArthritisReliable signal | 20 Apr 2027Rifaximin (Xifaxan) · Approved | — | — | — | — |
Alfresa PharmaPrivate | 1 asset: 1 approved | Approved assets only | Apr 2027Epinephrine · Approved | — | — | — | — |
| 2 assets: 2 Ph 1 | ALF202Phase 1 · Atherosclerotic Cardiovascular DiseaseWeak signal | None on record | — | — | — | — | |
Alligator BiosciencePrivate | 1 asset: 1 Ph 2 | ALG.APV-527Phase 1/2 · Solid Tumors | None on record | — | — | — | — |
Allodynic Therapeutics, LLCPrivate | 1 asset: 1 Ph 3 | Naltrexone/Acetaminophen (ALLOD-2)Phase 2/3 · Migraine | None on record | — | — | — | — |
Allorion TherapeuticsPrivate | 1 asset: 1 Ph 2 | AVZO-021Phase 1/2 · HR+/HER2- Metastatic Breast Cancer | 31 Jan 2028AVZO-021 · Phase 1/2 | — | — | — | — |
AllRock BioPrivate | 1 asset: 1 Ph 2 | ROC-101Phase 2 · Pulmonary Arterial Hypertension | Mar 2027ROC-101 · Phase 2 | — | — | — | — |
Allyx TherapeuticsPrivate | 1 asset: 1 Ph 1 | BMS-984923Phase 1 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
Almac DiscoveryPrivate | 1 asset: 1 Ph 2 | ZedoresertibPhase 1/2 · HR+/HER2- Metastatic Breast Cancer | Dec 2027Zedoresertib · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 3 | ZorifertinibPhase 2/3 · Non-Small Cell Lung CancerPartial signal | 23 Apr 2028Zorifertinib · Phase 1 | — | — | — | — | |
Alphyn BiologicsPrivate | 1 asset: 1 Ph 2 | zabalafinPhase 2 · Atopic Dermatitis | None on record | — | — | — | — |
Alterome Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | ALTA3263Phase 1 · Non-Small Cell Lung Cancer | May 2029ALTA3263 · Phase 1 | — | — | — | — |
AltruBioPrivate | 1 asset: 1 Ph 2 | ALTB-268Phase 2 · Ulcerative ColitisWeak signal | None on record | — | — | — | — |
Amandala Neuro LimitedPrivate | 1 asset: 1 Ph 2 | ELE-101Phase 1/2 · Major Depressive Disorder | None on record | — | — | — | — |
Amicus TherapeuticsPrivate | 1 asset: 1 approved | Approved assets only | 31 Dec 2026Migalastat · Phase 3 | — | — | — | — |
AmorepacificPrivate | 1 asset: 1 Ph 3 | asivatrepPhase 3 · Atopic DermatitisReliable signal | None on record | — | — | — | — |
Amphista Therapeutics LtdPrivate | 1 asset: 1 Ph 1 | AMX-883Phase 1 · Acute Myeloid Leukemia | 4 Dec 2028AMX-883 · Phase 1 | — | — | — | — |
AmyriAD Therapeutics B.V.Private | 1 asset: 1 Ph 2 | Inidascamine (RL-007)Phase 2 · Cognitive Impairment Associated with Schizophrenia | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.